Author

Jason W. Chen

Cornell UniversityORCID 0000-0001-9213-6252Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Assay:proteomics· 1

Frequent Co-Authors

Benjamin D. CosgroveiD· 2 shared Paula E. PetrellaiD· 2 shared Gabrielle O. Ravelo· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

3 top collaborators · 3 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Benjamin D. CosgroveORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJun 26, 2026

Combined agonism and antagonism of canonical and non-canonical progesterone receptors in triple-negative breast cancer cells potentiates cytotoxicity enhanced by PI3K inhibition

Paula E. Petrella, Jason W. Chen, Benjamin D. Cosgrove

The paper investigates the effects of combined PR agonism and antagonism on TNBC cell viability and PI3K inhibitor cytotoxicity, finding enhanced cytotoxicity when targeting both canonical and non-canonical PRs.

DOI 10.64898/2026.06.25.734635

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 28, 2024

Chemoresistance to additive PARP/PI3K dual inhibition in triple-negative breast cancer cell lines is associated with adaptive stem cell-like prevalence

Paula E. Petrella, Jason W. Chen, Gabrielle O. Ravelo, Benjamin D. Cosgrove

This study examines the chemoresistance of triple-negative breast cancer cell lines to PARP/PI3K dual inhibition and identifies treatment schedules that enhance its efficacy.

1 citation

humanbulk RNA-seq

𝕏 PostBluesky